Bank of America
LIMNW

Bank of America’s Liminatus Pharma Warrants LIMNW Stock Holding History

Bank of America’s Portfolio LIMNW Stock Details LIMNW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-100
Closed -$4 – 7198
2025
Q4 		$4 Sell
100
-100
-50% -$10 ﹤0.01% 7249
2025
Q3 		$29 Sell
200
-100
-33% -$20 ﹤0.01% 8120
2025
Q2 		$72 Buy
+300
New +$59 ﹤0.01% 8034

Other funds holding LIMNW

AC
Aristeia Capital Greenwich, Connecticut $4.82B AUM 24.91% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
SCM
Saba Capital Management New York $3.62B AUM 12.96% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.02% 1-Year Est. Return
MCM
Moore Capital Management New York $4.92B AUM 35.4% 1-Year Est. Return
MI
MMCAP International Grand Cayman, Cayman Islands $1.16B AUM 76.63% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
PC
Periscope Capital Toronto, Ontario, Canada $902M AUM 6.27% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $10.4B AUM 4.78% 1-Year Est. Return

Bank of America's LIMNW Position: Q1 2026 in Review

Bank of America sold out of Liminatus Pharma Warrants (LIMNW) in Q1 2026, closing a stake of 100 shares — an estimated $4 sold.

Bank of America first reported a position in LIMNW in Q2 2025 and held it in 3 quarters. The position peaked at $72 in Q2 2025. 21 funds tracked by Wall St. Rank hold LIMNW as of Q1 2026.

  • Bank of America reported no remaining Liminatus Pharma Warrants position as of Q1 2026 after selling out during the quarter.
  • Bank of America sold 100 Liminatus Pharma Warrants shares in Q1 2026, an estimated $4.
  • Bank of America first reported a position in Liminatus Pharma Warrants in Q2 2025 and held it in 3 quarters.
  • Bank of America's Liminatus Pharma Warrants position peaked at $72 in Q2 2025.
  • 21 funds tracked by Wall St. Rank held Liminatus Pharma Warrants as of Q1 2026.

Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.